Acquired
Novo Nordisk (Ozempic)
David Rosenthal
And that grew naturally out of the diabetes and the insulin research and Lada's work and sort of in this organic fashion that is so different than the rest of the pharma industry. But the net result of this now is that, yes, insulin is still a large business within Novo Nordisk, but it is a GLP-1 company. So when Wegevi finally launches in the U.S.
0
💬
0
Comments
Log in to comment.
There are no comments yet.